Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

Inclusion Criteria: * Females, 18-49 years of age with HPV16 infection and cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1) * HPV16 infection has been confirmed at least twice by a validated HPV test separated by at least 3 months * Satisfactory colposcopy * No clinically significant out of range haematological, renal or hepatic laboratory tests * Normal screening ECG or screening ECG with no clinically significant findings, as judged by the investigator * Negative serum pregnancy test at screening * Agree to use a reliable form of contraception during the whole study period. * Provides written informed consent Exclusion Criteria: * Any vaccination within 6 weeks of day 0 * Active significant viral infections including influenza, CMV, and EBV within 30 days of receiving study treatment * Co-infection with hepatitis B, hepatitis C, or HIV or having other immune deficient states * Current Bacterial Vaginosis (BV) infection * Current high-grade cervical intraepithelial neoplasia (CIN2/3) * Prior history of or current malignancy, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), atypical glandular cells (AGC), adenocarcinoma in situ (AIS) or any suspicion of either micro-invasive or invasive disease * Pregnancy, breastfeeding * Influenza-like illness (ILI) within 3 months of day 0 * Known hypersensitivity to oseltamivir or any of its components * Any anatomical condition of the cervix, including that resulting from previous cervical surgery, congenital malformation or other condition, that would interfere with a complete evaluation of the cervix * Current pelvic inflammatory disease, cervicitis, or other gynaecological infection as per colposcopy and clinical examination * Serious, concomitant disorder, including active systemic infection requiring treatment * Presence of acute or chronic bleeding or clotting disorder, or use of blood thinners within 2 weeks of day 0 * A proven or suspected autoimmune disease * Immunosuppression including any concurrent condition requiring the continued use of systemic or topical steroids, or the use of immunosuppressive agents, disease modifying doses of anti-rheumatic drugs, and biologic disease modifying drugs. Any immunosuppressive agents containing corticosteroids or monoclonal antibodies specific for the treatment of obstructive airway, ear or vestibular diseases are permissible. * Acute or history of Herpes genitalis * Prior major surgery within 4 weeks of day 0 * Administration of any blood product within 3 months of enrolment * Any current significant cardiac, hepatic or renal disease or history of clinically significant, medically unstable disease * Any current or history of neurological disease including history of seizures * Participation in another experimental protocol/use of investigational drug during the prior two months